

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A01N 43/80, 25/28	A1	(11) International Publication Number: WO 00/10392 (43) International Publication Date: 2 March 2000 (02.03.00)
(21) International Application Number: PCT/US99/18017 (22) International Filing Date: 13 August 1999 (13.08.99) (30) Priority Data: 60/096,973 18 August 1998 (18.08.98) US (71) Applicant: FMC CORPORATION [-/US]; 1735 Market Street, Philadelphia, PA 19103 (US). (72) Inventor: SZAMOSI, Janos; 4 Baltusrol Avenue, Washington, NJ 07882 (US). (74) Agent: PINTZUK, Marcia, D.; FMC Corporation, 1735 Market Street, Philadelphia, PA 19103 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: COMBINATION OF TWO OR MORE ACTIVE INGREDIENTS USING MICROENCAPSULATED FORMULATIONS (57) Abstract <p>Provided is a method of encapsulating clomazone and a second biological agent comprising: (a) mixing (i) an aqueous phase, (ii) an emulsifier and (iii) a water-immiscible phase containing clomazone, the second biological agent, and at least one first polyfunctional compound; (b) forming a dispersion of water-immiscible droplets throughout the aqueous phase; and (c) adding at least one second polyfunctional compound into the dispersion and reacting the second polyfunctional compound(s) with the first polyfunctional compound(s) to form a polymer shell around the water-immiscible droplets. Further provided is a method of preparing an agricultural composition comprising encapsulated clomazone and a second biological agent, the method comprising: (a) providing a suspension of clomazone capsules comprising solutes, diluents or carriers; (b) providing a composition of suspended particles of the second biological agent; (c) adjusting solutes, diluents or carriers in the particle suspension so that the osmolarity of the particle suspension is sufficiently like that of the capsule suspension so that the capsules are not disrupted when the suspensions of steps (a) and (b) are mixed; and (d) mixing the suspensions of steps (a) and (b).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

COMBINATION OF TWO OR MORE ACTIVE INGREDIENTS USING MICROENCAPSULATED FORMULATIONS

5 This application claims benefit of U.S. Provisional Application No.
60/096,973, filed August 18, 1998.

 The present application relates to the field of active ingredient formulations
for use in agricultural or pharmaceutical applications.

 Microencapsulated formulations have been developed to answer issues
10 concerning controlled release, volatility, or toxicity of certain active ingredients,
thereby providing a means for using such ingredients. Formulations of this type that
have been described for the herbicide clomazone (see US 5,597,780), for example,
are fragile when in concentrated form. The fragility of the microcapsules interferes
with preparing concentrated compositions containing with a second component,
15 because the preparation process tends to release the formerly microencapsulated
active ingredient. The present invention describes methods and materials for making
such two component concentrates. Also, hitherto microcapsules having two or more
different active ingredients have not been described. The present invention provides
methods and materials for making such two component microcapsules.

20

Summary of the Invention

 The invention provides a method of encapsulating clomazone and a second
biological agent comprising:

- 25 mixing (i) an aqueous phase, (ii) an emulsifier and (iii) a water-
immiscible phase containing clomazone, the second
biological agent, and at least one first polyfunctional
compound;
 forming a dispersion of water-immiscible droplets throughout the
aqueous phase; and
30 adding at least one second polyfunctional compound into the
dispersion and reacting the second polyfunctional

compound(s) with the first polyfunctional compound(s) to form a polymer shell around the water-immiscible droplets.

The first or second polyfunctional compounds are "polyfunctional" in the sense that each has the capacity to react to form a covalent bond with two or more compounds of the same class as the other polyfunctional compound. For instance, the first polyfunctional compound can be a polyfunctional isocyanate, while the second polyfunctional compound can be an amine.

Also provided is an agricultural composition comprising capsules containing, together, clomazone and a second biological agent.

The invention further provides a method of preparing an agricultural composition comprising encapsulated clomazone and a second biological agent, the method comprising:

- (a) providing a suspension of clomazone capsules comprising solutes, diluents or carriers;
- (b) providing a composition of suspended particles of the second biological agent;
- (c) adjusting solutes, diluents or carriers in the particle suspension so that the osmolarity of the particle suspension is sufficiently like that of the capsule suspension so that the capsules are not disrupted when the suspensions of steps (a) and (b) are mixed; and
- (d) mixing the suspensions of steps (a) and (b).

In one embodiment, the method further comprises:

- (e) milling composition of suspended particles at least until the particles are no more than about 100 μm , in some cases as small as 1 μm , in size.

Accordingly, also provided is an agricultural composition comprising an aqueous suspension of (a) capsules of clomazone and (b) particles, which are distinct from the clomazone capsules, comprising a second biological agent.

Definitions

The following terms shall have, for the purposes of this application, the respective meanings set forth below.

- **Agricultural agent** shall mean a bioactive agent used in agriculture, such as a herbicide, insecticide or fungicide.
- **Bioactive agent** shall mean a substance such as a chemical that can act on a cell, virus, organ or organism, including but not limited to insecticides, fungicides and herbicides, which substance creates a change in the functioning of the cell, virus, organ or organism.
- A particle (which may be liquid) containing a bioactive agent is **encapsulated** if it is coated with or admixed with an amount of polymer which slows release of the encapsulated agent, reduces the toxicity of the agent to mammals, stabilizes the form of the agent, inhibits crystallization of the agent, reduces the volatility of the agent or produces any other benefit of coating a chemical agent with a polymer or admixing the chemical agent with the polymer.
- A **microcapsule** shall mean an encapsulated particle which is no more than about 1,000 μm in size, preferably no more than about 20 μm in size.
- A **particle size limit** for a composition shall mean that at least about 90% of the particles in the composition shall be within the size range cited, where size is measured by light scattering using an instrument, such as a Laser Scattering Particle Size Distribution Analyser, Horiba Instrument Corp., Irvine, CA.
- The use of the modifier "**about**" with respect to pH is used herein to indicate a variance of at least one half a pH unit, and preferably indicates a variance of one half a pH unit. In other contexts herein where the modifier "about" is used to qualify a non-log unit, the "about" is intended to indicate a variance of $\pm 15\%$, yet more preferably a variance of $\pm 10\%$.

Detailed Description of the Invention

A first embodiment of the invention involves the co-microencapsulation of clomazone and another agricultural agent such as a herbicide (for example,

dimethachlor). In one preferred embodiment, the co-microencapsulated formulations of the invention are made according to the following steps:

- mixing (i) an aqueous phase, (ii) an emulsifier and (iii) a water-immiscible phase (also referred to as an "organic" phase) containing clomazone,
- 5 a second agricultural agent, and a polyfunctional isocyanate;
- forming a dispersion of water-immiscible droplets throughout the aqueous phase; and
- adding an amine, preferably a polyfunctional amine, into the dispersion and
- reacting the amine with the polyfunctional isocyanate to form a
- 10 polyurea shell around the water-immiscible droplets.

Note that while an amine can be a "polyfunctional compound" as described above, the term "polyfunctional amine" refers to compounds with two or more amine functional groups. In a particular embodiment, the invention can comprise the steps of (a) preparing an aqueous phase containing an emulsifier and an antifoam agent;

- 15 (b) preparing a water-immiscible phase containing clomazone, a second agricultural agent, and a polyfunctional isocyanate; (c) emulsifying the aqueous phase with the water-immiscible phase to form a dispersion of water-immiscible droplets throughout the aqueous phase; and (d) agitating the dispersion while adding to it, either neat or in an aqueous solution, an amine or mixture of amines, thus forming a
- 20 polyurea shell around the water-immiscible droplets. Once the microcapsules are formed, the suspension can be cured, i.e., incubated over time under polymerization supporting conditions, including, for example, moderate heating. One or more additives, such as propylene glycol, xanthan gum, urea, bactericides, amphoteric surfactants, dyes or ionic dispersing agents (e.g., alkyl naphthalene sulfonate), can
- 25 be added to the microcapsules. The pH of the formulation is then, in some preferred embodiments, adjusted to neutral, e.g. about pH 6.5 to about 7.5, for example, to improve stability.

The clomazone/herbicide combination is preferably at a ratio of from about 1 to about 20 (~1:~20) to about 20 to about 1 (~20:~1) clomazone to herbicide. For

- 30 example the ratio of clomazone to dimethachlor can be about 1 to about 12.5

clomazone to dimethachlor. In addition the clomazone/herbicide combination can be, for example, about 5 to about 40, preferably about 31.0, weight percent of the total formulation.

The co-microencapsulated formulations can contain, for example, one or more of the following additional components in the following amounts (in weight percent) based on the total weight of the formulation: 1) emulsifier - up to about 1.5, preferably about 1, weight percent; 2) antifoam agent - up to about 0.5, preferably about 0.25, weight percent; 3) polyfunctional isocyanate - about 2 to about 5, preferably about 4, weight percent; 4) polyfunctional amine - about 1.5 to about 4, preferably about 2.4, weight percent; 5) water - about 40 to about 60, preferably about 45 (such as about 45.1), weight percent. Example 1 illustrates the process for preparing the co-microencapsulated formulations of the present invention.

Preferably, the capsules formed by the polyurea shell are about 1 μm to about 100 μm , more preferred about 1 μm to about 20 μm .

Preferably, the polyfunctional isocyanate favors partitioning to the water-immiscible phase over the aqueous phase. While preferably the polyfunctional isocyanate favors partitioning into the immiscible phase, preferably such partitioning is not as strong as the partitioning by clomazone. Appropriate polyfunctional isocyanates include, for example, polymethylene polyphenyl isocyanate (PMPPI), 4,4'-diphenylmethane diisocyanate, 2,4'-diphenylmethane isocyanate, hexamethylene diisocyanate and methane diisocyanate. Preferably, the polyfunctional isocyanate is a difunctional isocyanate such as a bis compound. Appropriate amines include, for example, hexamethylene diamine (HMPA), triethylamine, dimethylamine, diethylenetriamine and triethylene tetramine. Preferably, the polyfunctional amine is hexamethylene diamine.

Appropriate herbicides for use as the second agricultural agent include, for example, dimethachlor (2-chloro-N-(2,6-dimethylphenyl)-N-(2-methoxyethyl)acetamide), pendimethalin (N-(1-ethylpropyl)-3,4-dimethyl-2,6-

dinitrobenzamine) and trifluralin (2,6-dinitro-N,N-dipropyl-4-(trifluoromethyl)benzenamine).

Preferably, the curing process comprises heating from about 15 °C to about 60 °C, more preferably about 25 °C to about 50 °C, for from about 30 minutes to about ten hours, preferably about 1 to about 2 hours.

A second "premixture" embodiment of the invention involves the preparation of a pre-mixture which comprises a combination of clomazone capsule suspension (CS), which can be a commercially available CS, and a suspension of particles of another agricultural agent, such as without limitation the herbicides sulfentrazone (N-[2,4-dichloro-5-[4-(difluoromethyl)-4,5-dihydro-3-methyl-5-oxo-1H-1,2,4-triazol-1-yl]phenyl]methanesulfonamide), propanil (N-(3,4-dichlorophenyl) propanamide), carfentrazone-ethyl (the ethyl ester of 2-dichloro-5-[4-(difluoromethyl)-4,5-dihydro-3-methyl-5-oxo-1H-1,2,4-triazol-1-yl] 4-fluorobenzenepropanoic acid), or metribuzin (4-amino-6-(1,1-dimethylethyl)-3-(methylthio)-1,2,4-triazin-5(4H)-one). Ordinarily the microencapsulated formulation would not hold its integrity when combined with a particle suspension; however, as described herein both formulations maintain their integrity after they have been combined. In one preferred embodiment, the pre-mixture formulation is made according to the following steps:

- (a) providing a suspension of clomazone capsules comprising solutes, diluents or carriers;
- (b) providing a composition of suspended particles (which can be encapsulated) of a second agricultural agent;
- (c) adjusting solutes, diluents or carriers in the particle suspension so that the osmolarity of the particle suspension is sufficiently like that of the capsule suspension so that the capsules are not disrupted when the suspensions of steps (a) and (b) are mixed; and
- (d) mixing the suspensions of steps (a) and (b).

Preferably, the particles comprise a herbicide, which herbicide is preferably distinct from clomazone. Preferably, the particles are sized to no more than about 100 µm,

more preferably no more than about 10 μm , which sizing prevents damage to the clomazone capsules. In certain embodiments, the method will comprise grinding, milling, abrading or like process (hereafter, "milling") the suspended particles at least until the size requirement is met.

5 The amount of the clomazone and herbicide present in the pre-mixture depends on the type of herbicide used. In general, the range can be from about 0.1 to about 80 herbicide to clomazone or vice versa depending on the herbicide. For example, when sulfentrazone is used the ratio can preferably be two to one clomazone to sulfentrazone; however when dimethachlor is used the ratio can
10 preferably be 12.5 to one dimethachlor to clomazone. Example 2 illustrates the process for preparing the pre-mixture formulations of the present invention.

 The preparation of the particle suspension can, for example, involve the following: a) combining the technical material, a copolymer surfactant, such as a calcium lignosulfonate, an ionic dispersing agent (e.g., alkyl naphthalene sulfonate),
15 an antifoam agent, and water; b) stirring the mixture for 5 minutes to two hours; c) intermittently milling the mixture until the particle size of the mixture is below 10 μm ; and then d) adding additional suitable materials, such as xanthan gum, propylene glycol, and calcium or sodium salts, that are contained in the clomazone CS formulation in order to make the two formulations as similar as possible so that
20 when the two formulations are combined there are no problems. The particle suspension can contain one or more of the above components in the following amounts based on the total weight of the particle suspension: 1) bioactive agent(s) such as agricultural agent(s) - about 2 to about 45, preferably about 30-35 weight percent; 2) antifoam agent - about 0.1 to about 1, preferably about 0.3, weight
25 percent; 3) polymeric surfactant - about 0.1 to about 5, preferably about 4, weight percent; 4) dispersing agent - about 0.1 to about 5, preferably about 0.5, weight percent; 5) water - about 30 to about 90, preferably about 43, weight percent; 6) antifreezes and/or thickeners - about 0.1 to about 9, preferably about 0.1 to 7.5,
30 more preferably 0.1, weight percent; 7) total metal ion salts (such as calcium and/or sodium salts) - about 1 to about 15, preferably about 10, weight percent. Such

antifreezes and/or thickeners preferably include, without limitation: 6a) propylene glycol - about 2 to about 5, preferably about 4.5, weight percent; 6b) xanthan gum - about 2 to about 4, preferably about 3, weight percent.

5 The invention having been described hereinabove, is further illustrated in the following examples which are not intended to be limitative in any manner.

EXAMPLE 1

10 This example sets forth one protocol for preparation of a 250 grams/liter clomazone and dimethachlor capsule suspension (250 CS) formulation, in accordance with the present invention.

A stock mixture of clomazone technical and dimethachlor was prepared by stirring 45.0 grams of technical clomazone and 913 grams of commercially available dimethachlor. The solution was stored for later use.

15 The aqueous phase for co-microencapsulation was prepared in a four-liter stainless steel beaker by mixing 4.0 grams of a calcium lignosulfonate (Norlig® 11 DA, LignoTech USA, Rothschild, WI) and 1.0 gram of a 100% polydimethyl siloxane antifoam agent (Dow Corning® 1520, Dow Corning Corp., Midland, MI) in 170 grams of distilled water. The entire mixture was then transferred to a one-liter
20 beaker. The mixture was mixed for one minute at high speed, then a pre-blended solution of 160.0 grams of the clomazone/dimethachlor stock mixture and 16.0 grams of polymethylene polyphenyl isocyanate (PMPPI, Papi® 27, Dow Chemical Co., Midland, MI) was added, and the mixture was emulsified for five minutes. The mixture was then placed in a one-liter 3-necked roundbottom flask equipped
25 with a mechanical stirrer, and 9.6 grams of a 70% aqueous solution of hexamethylenediamine (HMDA) in 9.6 grams of water was added during a 30 second period. Upon completion of the addition, the mixture was heated to 60 °C and held for one hour. After this time, the mixture was cooled to 25 °C and 14.0 grams of aqueous 2% xanthan gum (Kelzan® S, Monsanto, St. Louis, MO) was
30 added. The formulation was then mixed for about 10 minutes and then stored.

EXAMPLE 2

This example sets forth one protocol for preparation of a pre-mixture clomazone and sulfentrazone formulation, in accordance with the present invention.

A suspension concentrate (SC) formulation of sulfentrazone was prepared by stirring a mixture of 350.0 grams of sulfentrazone technical, 40.0 grams of an nonionic polymeric surfactant (Atlox® 4913, ICI Americas Inc., Wilmington, DE, a subsidiary of Imperial Chemical Industries Surfactants), 5.0 grams of an alkyl naphthalene sulfonate dispersing agent (Atlas® 435, ICI Americas Inc.), and 3.0 grams of a 100% polydimethyl siloxane antifoam agent (Dow Corning® 1520) in 429.5 grams of water for four hours. At the conclusion of this period, the mixture was intermittently milled until the particle size was below 10 µm. Once the particle size was below 10 µm, 45.0 grams of propylene glycol, 30.0 grams of 1% aqueous xanthan gum (Kelzan® S), 50.0 grams of calcium chloride, and 47.5 grams of sodium nitrate were added. Then 772.0 grams of this formulation was transferred to a four-liter stainless-steel beaker. The formulation was stirred for one minute, then 1403 grams of a suspension of clomazone capsules, Command® 3 ME (FMC Corporation, Agricultural Products Group, Philadelphia, PA) was added. Upon completion of addition, the formulation was then mixed until uniform (about one hour) and stored.

While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations in the preferred devices and methods may be used and that it is intended that the invention may be practiced otherwise than as specifically described herein.

Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the claims that follow.

WHAT IS CLAIMED:

1. A method of encapsulating clomazone and a second agricultural agent comprising:
 - (i) an aqueous phase, (ii) an emulsifier and (iii) a water-immiscible phase containing clomazone, the second agricultural agent, and at least one first polyfunctional compound;
 - forming a dispersion of water-immiscible droplets throughout the aqueous phase; and
 - adding at least one second polyfunctional compound into the dispersion and reacting the second polyfunctional compound(s) with the first polyfunctional compound(s) to form a polymer shell around the water-immiscible droplets.
2. The method of claim 1, wherein at least one first polyfunctional compound is a polyfunctional isocyanate.
3. The method of claim 2, wherein at least one second polyfunctional compound is an amine.
4. The method of claim 1, further comprising:
 - agitating the dispersion during the adding and reacting step.
5. The method of claim 1, wherein the second agricultural agent is a herbicide.
6. The method of claim 5, wherein the herbicide is dimethachlor.
7. An agricultural composition comprising capsules containing, together, clomazone and a second agricultural agent:

8. The agricultural composition of claim 7, having the following composition:

- encapsulated clomazone and the second agricultural agent, combined, about 20 to about 40 weight percent;
- polyfunctional isocyanate, about 2 to about 5 weight percent;
- amine, about 1.5 to about 4 weight percent; and
- water, about 40 to about 60 weight percent.

9. The composition of claim 8, wherein the composition further includes:

- emulsifier, up to about 1.5 weight percent; and
- antifoam agent, up to about 0.5 weight percent.

10. A method of preparing an agricultural composition comprising encapsulated clomazone and a second agricultural agent; the method comprising:

- (a) providing a suspension of clomazone capsules comprising solutes, diluents or carriers;
- (b) providing a composition of suspended particles of the second agricultural agent;
- (c) adjusting solutes, diluents or carriers in the particle suspension so that the osmolarity of the particle suspension is sufficiently like that of the capsule suspension so that the capsules are not disrupted when the suspensions of steps (a) and (b) are mixed; and
- (d) mixing the suspensions of steps (a) and (b).

11. The method of claim 10, further comprising:

- (e) milling composition of suspended particles at least until the particles are no more than about 100 μm in size.

12. The method of claim 11, wherein the milling is conducted at least until the particles are no more than about 10 μm in size.
13. An agricultural composition comprising an aqueous suspension of (a) capsules of clomazone and (b) particles, which are distinct from the clomazone capsules, comprising a second agricultural agent.
14. The agricultural composition of claim 13, wherein the second agricultural agent comprises a herbicide selected from the group consisting of sulfentrazone, propanil, carfentrazone-ethyl (the ethyl ester of 2-dichloro-5-[4-(difluoromethyl)-4,5-dihydro-3-methyl-5-oxo-1H-1,2,4-triazol-1-yl]-4-fluorobenzenepropanoic acid), and metribuzin.
15. The agricultural composition of claim 13, having the following composition:
- clomazone and second agricultural agent, about 2 to about 45 weight percent;
 - antifoam agent, about 0.1 to about 1.0 weight percent;
 - polymeric surfactant, about 0.1 to about 5 weight percent;
 - dispersing agent, about 0.1 to about 5 weight percent;
 - water, about 30 to about 90 weight percent;
 - antifreezes and/or thickeners, about 0.1 to about 9 weight percent;
 - and total metal ion salts, about 1 to about 15 weight percent.

INTERNATIONAL SEARCH REPORT

International Application No.

PC./US 99/18017

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A01N43/80 A01N25/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 583 090 A (STERN ALAN J ET AL) 10 December 1996 (1996-12-10) claims 21,22 column 9, line 26 - line 45	1-15
X	WO 90 08468 A (ICI AMERICA INC) 9 August 1990 (1990-08-09) claims page 5, line 14 - line 16	1-15
X	EP 0 017 409 A (MONSANTO CO) 15 October 1980 (1980-10-15) claims page 8, line 10 - line 20	1-9
X	WO 95 13698 A (ZENECA LTD) 26 May 1995 (1995-05-26) claims	1-9



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 November 1999

Date of mailing of the international search report

18/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Decorte, D

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 99/18017

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5583090 A	10-12-1996	AU 698102 B	22-10-1998
		AU 6158396 A	30-01-1997
		BR 9609387 A	18-05-1999
		CA 2205052 A	12-02-1997
		EP 0854675 A	29-07-1998
		WO 9701274 A	16-01-1997
		US 5783520 A	21-07-1998
WO 9008468 A	09-08-1990	US 5049182 A	17-09-1991
		AT 139080 T	15-06-1996
		AU 646390 B	24-02-1994
		AU 5103890 A	24-08-1990
		DE 69027426 D	18-07-1996
		DE 69027426 T	31-10-1996
		DK 456756 T	21-10-1996
		EP 0456756 A	21-11-1991
		ES 2087908 T	01-08-1996
		JP 4504417 T	06-08-1992
		US 5223477 A	29-06-1993
EP 0017409 A	15-10-1980	US 4280833 A	28-07-1981
		AR 224644 A	30-12-1981
		AT 2774 T	15-04-1983
		AU 532474 B	29-09-1983
		AU 5682880 A	02-10-1980
		BR 8001786 A	18-11-1980
		CA 1165581 A	17-04-1984
		CS 249110 B	12-03-1987
		DD 149471 A	15-07-1981
		DK 127780 A,B,	27-09-1980
		ES 489855 A	16-12-1980
		FI 800920 A,B,	27-09-1980
		GR 67254 A	26-06-1981
		IL 59510 A	31-03-1983
		IN 152084 A	15-10-1983
		JP 1482929 C	27-02-1989
		JP 55129146 A	06-10-1980
		JP 63032761 B	01-07-1988
		KR 8400114 B	16-02-1984
		NO 800856 A	29-09-1980
		NO 840342 A	29-09-1980
		NZ 193261 A	23-11-1982
		PH 17996 A	28-02-1985
		PT 71010 A	01-04-1980
		RO 81047 A	01-06-1983
		SU 1039436 A	30-08-1983
		US 4417916 A	29-11-1983
		YU 83180 A	29-02-1984
		ZA 8001750 A	26-08-1981
WO 9513698 A	26-05-1995	AT 167980 T	15-07-1998
		AU 678074 B	15-05-1997
		AU 8111094 A	06-06-1995
		BG 100562 A	31-12-1996
		BR 9408051 A	24-12-1996
		CA 2176513 A	26-05-1995
		CN 1135160 A	06-11-1996
		CZ 9601396 A	12-02-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/18017

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9513698 A		DE 69411583 D	13-08-1998
		DE 69411583 T	18-02-1999
		EP 0730406 A	11-09-1996
		ES 2119354 T	01-10-1998
		HU 74707 A	28-02-1997
		JP 9505074 T	20-05-1997
		NO 961963 A	14-05-1996
		NZ 275848 A	29-01-1997
		PL 314424 A	02-09-1996
		SI 9420069 A	31-12-1996
		US 5846554 A	08-12-1998
		ZA 9409019 A	17-07-1995

THIS PAGE BLANK (USPTO)